LOS ANGELES, Nov. 2 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "We believe Raptor's operational approach will serve as the template for all small cap biotechnology companies as it promotes operational efficiency, reduced operating costs and efficient allocation of human resources. Also, Raptor now has a Phase II candidate for 2008 in Convivia(TM), which will treat a large patient population in a billion dollar plus market," stated Ross Silver, Director of Research for Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com.
Raptor's CEO, Dr. Christopher M. Starr, is presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at The New York Palace Hotel on Monday, November 5, 2007 at 4:05 p.m. ET. A webcast of Dr. Starr's presentation, including slides, will be posted on Raptor's website, live and archived for 90 days.
Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of Raptor Pharmaceutical Inc. ("Raptor Inc."), a development stage biotechnology company which bioengineers novel drug candidates and drug- targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company formed to develop clinical-stage products to marketing approval and commercialization. Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand its coverage in specific disease indications.
Bennu's initial clinical program includes the treatment of aldehyde dehydrogenase ("ALDH2") deficiency. For additional information, please visit http://www.raptorpharma.com.
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2007 PR Newswire.
All rights reserved